Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

We came across a bullish thesis on Schrödinger, Inc. (SDGR) on Value Degen’s Substack by Unemployed Value Degen. In this ...

Eli Lilly (LLY) stock gained as Citi resumed its covderage with a buy rating and $1,060 price target, citing optimism for its ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral ...

Eli Lilly and Company (NYSE:LLY) was a part of 100 hedge fund portfolios at the end of Q2 2024, down from 109 in the previous ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

Sept 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug ...